{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:33:55Z","timestamp":1790386435578,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"10","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,28]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment with enasidenib, a selective mutant isocitrate dehydrogenase isoform 2 (IDH2) inhibitor, has been associated with the development of differentiation syndrome (DS) in patients with acute myeloid leukemia (AML). Studies on the incidence and clinical features of DS are limited in this setting, and diagnosis is challenging because of nonspecific symptoms. This study assessed the incidence, diagnostic criteria, risk factors, and correlation with clinical response of DS based on the pooled analysis of 4 clinical trials in patients with IDH2-mutated AML treated with enasidenib as monotherapy, or in combination with azacitidine or with chemotherapy. Across the total AML population, 67 of 643 (10.4%) had \u22651 any-grade DS event, with highest incidence in patients who received enasidenib plus azacitidine and lowest incidence in patients who received enasidenib plus chemotherapy (13\/74 [17.6%] and 2\/93 [2.2%]). The most common symptoms of DS were dyspnea\/hypoxia (80.6%) and pulmonary infiltrate (73.1%). Median time to onset of first DS event across all studies was 32\u00a0days (range, 4-129). Most patients (88.1%) received systemic steroids for treatment of DS. Evaluation of baseline risk factors for DS identified higher levels of bone marrow blasts and lactate dehydrogenase as independent factors associated with increased grade 3 to 5 DS risk. Overall, these results suggest that DS associated with IDH inhibition is manageable, given the benefits of enasidenib treatment in IDH2-mutated AML. We further characterized enasidenib-related DS in these patients and identified risk factors, which could be used for DS management in clinical practice. These trials were registered at www.ClinicalTrials.gov as # NCT01915498, NCT02577406, NCT02677922, and NCT02632708.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011914","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T20:17:41Z","timestamp":1710965861000},"page":"2509-2519","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Differentiation syndrome associated with treatment with <i>IDH2<\/i> inhibitor enasidenib: pooled analysis from clinical trials"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"first","affiliation":[{"name":"1Department of Hematology, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-6447","authenticated-orcid":false,"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[{"name":"2Leukemia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-4942","authenticated-orcid":false,"given":"St\u00e9phane","family":"de Botton","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"5Section of Hematology, Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhu","sequence":"additional","affiliation":[{"name":"6Bristol Myers Squibb, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Prebet","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7085-0479","authenticated-orcid":false,"given":"Carlos E.","family":"Vigil","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Bluemmert","sequence":"additional","affiliation":[{"name":"8Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"9Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"2024052418454094700_bib1","unstructured":"American Cancer Society\n          . Key statistics for acute myeloid leukemia (AML). Accessed 13 December 2022. https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/about\/key-statistics.html."},{"issue":"3","key":"2024052418454094700_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"14","key":"2024052418454094700_bib3","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024052418454094700_bib4","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2024052418454094700_bib5","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-Ccass therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"2024052418454094700_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \"retinoic acid syndrome\" in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann Intern Med"},{"issue":"4","key":"2024052418454094700_bib7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"issue":"27","key":"2024052418454094700_bib8","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1182\/blood-2009-02-204834","article-title":"Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome","volume":"114","author":"Luesink","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2024052418454094700_bib9","doi-asserted-by":"crossref","first-page":"e2011059","DOI":"10.4084\/mjhid.2011.059","article-title":"The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature","volume":"3","author":"Montesinos","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"2024052418454094700_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ajh.26142","article-title":"Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia","volume":"96","author":"Fathi","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"2024052418454094700_bib11","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"2024052418454094700_bib12","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicenter, AG221-C-001 trial","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol"},{"issue":"16","key":"2024052418454094700_bib13","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2024052418454094700_bib14","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2009-07-216457","article-title":"How I treat acute promyelocytic leukemia","volume":"114","author":"Tallman","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2024052418454094700_bib15","first-page":"3342","article-title":"Incidence of differentiation syndrome associated with treatment regimens in acute myeloid leukemia: a systematic review of the literature","volume":"9","author":"Gasparovic","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"2024052418454094700_bib16","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2024052418454094700_bib17","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"issue":"24","key":"2024052418454094700_bib18","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"2024052418454094700_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.exphem.2021.03.003","article-title":"Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA","volume":"98","author":"MacBeth","year":"2021","journal-title":"Exp Hematol"},{"issue":"11","key":"2024052418454094700_bib20","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukemia (AG221-AML-005): a single-arm, phase 1b and randomized, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024052418454094700_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024052418454094700_bib22","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024052418454094700_bib23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/ejh.12598","article-title":"Differentiation syndrome in acute myeloid leukemia after treatment with azacitidine","volume":"95","author":"Laufer","year":"2015","journal-title":"Eur J Haematol"},{"issue":"1","key":"2024052418454094700_bib24","doi-asserted-by":"crossref","first-page":"e2011048","DOI":"10.4084\/mjhid.2011.048","article-title":"Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment","volume":"3","author":"Rego","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"18","key":"2024052418454094700_bib25","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2013-10-512640","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"123","author":"Sanz","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2024052418454094700_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br J Haematol"},{"issue":"21","key":"2024052418454094700_bib27","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1182\/blood.V124.21.3737.3737","article-title":"Evaluation of pharmacokinetic-pharmacodynamic (PKPD) relationship of an oral, selective, first-in-class, potent IDH2 inhibitor, AG-221, from a phase 1 trial in patients with advanced IDH2 mutant positive hematologic malignancies","volume":"124","author":"Fan","year":"2014","journal-title":"Blood"},{"key":"2024052418454094700_bib28","author":"IDHIFA. Prescribing information","year":"2017"},{"issue":"6132","key":"2024052418454094700_bib29","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2509\/2226426\/blooda_adv-2023-011914-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2509\/2226426\/blooda_adv-2023-011914-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T18:45:59Z","timestamp":1716576359000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/10\/2509\/515370\/Differentiation-syndrome-associated-with-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011914","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]}}}